Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta‐Analysis

  title={Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta‐Analysis},
  author={Spyridoula Maraka and Naykky M Singh Ospina and Ren{\'e} Rodr{\'i}guez‐Guti{\'e}rrez and Caroline J. Davidge-Pitts and Todd B. Nippoldt and Larry J. Prokop and Hassan Murad},
  journal={The Journal of Clinical Endocrinology \& Metabolism},
Background: Transgender individuals receive cross‐sex hormonal therapy to induce desired secondary sexual characteristics despite limited data regarding its effects on cardiovascular health. Methods: A comprehensive search of several databases up to 7 April 2015 was conducted for studies evaluating the effect of sex steroid use on lipids, myocardial infarction, stroke, venous thromboembolism (VTE), and mortality in transgender individuals. Pairs of reviewers selected and appraised the studies… 

Figures and Tables from this paper

Cardiovascular disease in transgendered people: A review of the literature and discussion of risk

  • L. Seal
  • Medicine, Biology
    JRSM cardiovascular disease
  • 2019
The effect of gender affirming hormonal therapy in transgendered people is difficult to interpret due to the variety of hormone regimens used, the relative brevity of the periods of observation and the influence of confounding factors.

Effects of testosterone treatment on transgender males: A single-institution study

Gender-affirming hormone therapy is an effective and safe short-term treatment in Thai transgender men and an intramuscular testosterone enanthate 250 mg every 4 weeks is an alternative masculinizing regimen with decent efficacy and safety profile.

Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population

This review examines the impact of GAHT in the transgender population on CV outcomes and surrogate markers of CV health and reviews available data on changes in DNA methylation or RNA transcription induced by GAHT that may translate into changes in metabolic parameters that could increase CV risk.

An Observational Study of Hypertension and Thromboembolism Among Transgender Patients Using Gender-Affirming Hormone Therapy

The protective association between progestins and HTN among TW is reassuring, and more research is needed to examine the effect of recent progestin, specifically medroxyprogesterone acetate, on TE among transwomen.

Feminizing Hormone Therapy Prescription Patterns and Cardiovascular Risk Factors in Aging Transgender Individuals in Australia

A greater proportion of trans individuals ≥45 years of age were treated with transdermal estradiol, and the median dose was lower, which is important given the high prevalence of cardiometabolic risk factors in this age group, however cardiovascular risk management guidelines in this demographic are lacking.

Cardiovascular health in transgender people

  • M. Irwig
  • Medicine
    Reviews in Endocrine and Metabolic Disorders
  • 2018
The relationship between exogenous sex steroids and cardiovascular events and surrogate markers in trans (transgender) people is examined and there is strong evidence that estrogen therapy for trans women increases their risk for venous thromboembolism over 5 fold and transdermal estrogen likely carries a lower risk.

Effects of Gender-Affirming Hormones on Lipid, Metabolic, and Cardiac Surrogate Blood Markers in Transgender Persons.

Studies describing a higher risk for cardiometabolic and thromboembolic morbidity and/or mortality in transgender women (but not transgender men) mainly covered data on transgender women using the now obsolete ethinyl estradiol and are no longer valid.

The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis

The results indicate that hormone therapy may affect hemostasis in transgender persons, which could be an underlying mechanism explaining the increased cardiovascular risk in this population.

Cardiovascular disease risk factors among transgender women in Chiang Mai, Thailand.

Among transgender women, receiving HT was associated with enhanced levels of a subset of CVD risk factors, and more research is necessary to inform the need for novel CVD prevention and treatment strategies in transgender women.

Characteristics of Transgender Women Referred to Women's Heart Clinic




Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis.

Observational evidence warranting low confidence suggests that compared to transdermal ET, oral ET may be associated with increased risk of VTE and DVT, but not MI.

Effects of Cross-Sex Hormone Treatment on Transgender Women and Men

In transgender women, estrogen therapy, with or without antiandrogen therapy, was associated with lower BP, and in transgender men, testosterone therapy wasassociated with increased BMI.

Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals.

Both MtF and FtM transsexuals experience alterations in the serum lipid profile because of CSHT, with the changes in FtM patients possibly more relevant in terms of atherogenesis.

Long-term evaluation of cross-sex hormone treatment in transsexual persons.

Cross-sex hormone treatment appears to be safe in transsexual men, but a substantial number of transsexual women suffered from osteoporosis at the lumbar spine and distal arm, and more attention should be paid to decrease cardiovascular risk factors during hormone therapy management.

A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.

The increased mortality in hormone-treated MtF transsexuals was mainly due to non-hormone-related causes, but ethinyl estradiol may increase the risk of cardiovascular death, and use of testosterone in doses used for hypogonadal men seemed safe.

Exogenous estrogen effect on lipid /lipoprotein cholesterol in transsexual males

It is concluded that exogenous estrogens administered to transsexual males results in a female pattern of lipid/lipoprotein cholesterol and SHBG concentration, and the decreased total cholesterol/HDL ratio may imply a lower atherogenic potential and a lessened cardiovascular risk in males who take estrogens.

Effects of three different testosterone formulations in female-to-male transsexual persons.

One-year testosterone administration in FtM transsexuals appears to be very safe with no differences among the testosterone formulations used and the detection of subtle or long-term differences in the effects of the three formulations may require further larger and longer term studies in this and other populations.

Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials.

Current available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects, and patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.

Hormone therapy for preventing cardiovascular disease in post-menopausal women.

High quality evidence is found that hormone therapy in both primary and secondary prevention conferred no protective effects for all-cause mortality, cardiovascular death, non-fatal myocardial infarction, angina, or revascularisation; the findings are dominated by the three largest trials.